Amgen (AMGN) is making significant strides in its oncology research and development, focusing on transformative therapies for both solid and hematological cancers. Key advancements include T cell engagers, small molecules, and selective ADCs. The company’s existing cancer treatments like IMDELLTRA, LUMAKRAS, and BLINCYTO are being expanded, while AI and biomarker strategies are integrated to drive further innovation and pipeline growth.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
AMGN: Transformative oncology pipeline advances with T cell engagers, AI, and precision therapies
Amgen (AMGN) is making significant strides in its oncology research and development, focusing on transformative therapies for both solid and hematological cancers. Key advancements include T cell engagers, small molecules, and selective ADCs. The company’s existing cancer treatments like IMDELLTRA, LUMAKRAS, and BLINCYTO are being expanded, while AI and biomarker strategies are integrated to drive further innovation and pipeline growth.